Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →French pharmaceutical group Servier has agreed to acquire Symphogen, a privately held Danish biopharmaceutical company, in a move that strengthens its oncology…
French pharmaceutical group Servier said on Friday it had agreed to buy Denmark's Symphogen for an undisclosed amount to strengthen its cancer drug pipeline.…
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in advanced/metastatic recurrent biliary tract cancer (Servier…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Servier signed a definitive agreement to acquire 100% of Symphogen, a Danish therapeutic antibody discovery company, to boost its antibody capabilities and leverage Symphogen's R&D pipeline. The deal advanced Servier's strategic ambition to become a recognized oncology player. Symphogen became Servier's antibody center of excellence, retaining its Ballerup, Denmark HQ and operating as a standalone entity. Terms not disclosed.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier / Symphogen A/S (this deal) | 2020 | — | — |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| Servier / Symphogen A/S | 2006 | — | 66 |
| Servier / Pieris Pharmaceuticals, Inc. | 2017 | $1.7B | — |
| Servier / IDEAYA Biosciences, Inc. | 2025 | $530M | — |
← Browse all deals · How we score deals
More: 2020 deals · Servier deals · Oncology deals